TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03682393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: 100mg 1x3 hydrocortison intravenously for three days after mitral valve surgery or until atrial fibrillation onset

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 100mg 1x3 intravenous fysiologic saline for three days after mitral valve surgery or until atrial fibrillation onset
Study: NCT00477217

Intervention type: DRUG
Group type: OTHER
Intervention: Zoledronic acid
Study: NCT03737032

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta Burst Stimulation
Description: Theta Burst Stimulation, a form of Transcranial Magnetic Stimulation, will be applied to the dorsomedial prefrontal cortex. will include 600 pulses delivered in brief bursts of three pulses with a frequency of 50 Hz, at an intensity of 110% of resting motor threshold, and administered every 200 ms (5 Hz). Bursts will be delivered without interruption for a total duration of 40 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta Burst Stimulation
Description: Theta Burst Stimulation, a form of Transcranial Magnetic Stimulation, will be applied to the dorsomedial prefrontal cortex. will include 600 pulses delivered in brief bursts of three pulses with a frequency of 50 Hz, at an intensity of 110% of resting motor threshold, and administered every 200 ms (5 Hz). Bursts will be delivered without interruption for a total duration of 40 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta Burst Stimulation
Description: Theta Burst Stimulation, a form of Transcranial Magnetic Stimulation, will be applied to the dorsomedial prefrontal cortex. will include 600 pulses delivered in brief bursts of three pulses with a frequency of 50 Hz, at an intensity of 110% of resting motor threshold, and administered every 200 ms (5 Hz). Bursts will be delivered without interruption for a total duration of 40 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta Burst Stimulation
Description: Theta Burst Stimulation, a form of Transcranial Magnetic Stimulation, will be applied to the dorsomedial prefrontal cortex. will include 600 pulses delivered in brief bursts of three pulses with a frequency of 50 Hz, at an intensity of 110% of resting motor threshold, and administered every 200 ms (5 Hz). Bursts will be delivered without interruption for a total duration of 40 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta Burst Stimulation
Description: Theta Burst Stimulation, a form of Transcranial Magnetic Stimulation, will be applied to the dorsomedial prefrontal cortex. will include 600 pulses delivered in brief bursts of three pulses with a frequency of 50 Hz, at an intensity of 110% of resting motor threshold, and administered every 200 ms (5 Hz). Bursts will be delivered without interruption for a total duration of 40 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta Burst Stimulation
Description: Theta Burst Stimulation, a form of Transcranial Magnetic Stimulation, will be applied to the dorsomedial prefrontal cortex. will include 600 pulses delivered in brief bursts of three pulses with a frequency of 50 Hz, at an intensity of 110% of resting motor threshold, and administered every 200 ms (5 Hz). Bursts will be delivered without interruption for a total duration of 40 seconds.
Study: NCT01676597

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pentoxifylline and rifaximin
Description: Tab Rifaximin 400 mg thrice daily + Pentoxifylline 400 mg thrice daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline and placebo
Description: Tab Pentoxifylline 400 mg thrice daily + Placebo thrice daily for 12 weeks
Study: NCT00735189

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anticoagulation clinic care
Description: Patient receives care from the outpatient anticoagulation management service

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: patient receives usual anticoagulation care from their regular primary care physician
Study: NCT02263170

Intervention type: OTHER
Intervention: MRI (magnetic resonance imaging)
Description: Assessment of the sphincter morphology

Intervention type: OTHER
Intervention: US (ultra sound)
Description: Assessment of the sphincter morphology

Intervention type: OTHER
Intervention: FLIP (functional luminal imaging probe)
Description: Assessment of the biomechanical properties of the sphincter region

Intervention type: OTHER
Intervention: HRAM (high resolution anal manometry)
Description: Assessment of the biomechanical properties of the sphincter region
Study: NCT00059761

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT01753778

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryo-Touch III Device
Description: Treatment with Cryo-Touch III
Study: NCT01488474

Intervention type: PROCEDURE
Intervention: peripheral nerve stimulation
Description: defining the minimal current threshold for distal motor response

Intervention type: PROCEDURE
Intervention: peripheral nerve stimulation
Description: defining the minimal current threshold for distal motor response
Study: NCT04158648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab
Description: Four loading doses of emicizumab 3 milligrams per kilogram of body weight (mg/kg) will be administered subcutaneously (SC) once a week (QW) for 4 weeks followed by participant's preference of one of the three following maintenance SC dose regimens: 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W).
Study: NCT00345787

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Corresponding placebo is applied for 12weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Transdermal System
Description: Buprenorphine Transdermal System 5, 10 or 20mg/patch is applied for 12weeks
Study: NCT04088318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OQL011
Description: OQL011 is an ointment containing active ingredient.
Study: NCT00059761

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT03069339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol will start at starting dose of 3.125 mg BD followed by 6.25 mg BD followed by 12.5 mg BD if BP 90/60 mmHg and HR 55/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol will start at starting dose of 3.125 mg BD followed by 6.25 mg BD followed by 12.5 mg BD if BP 90/60 mmHg and HR 55/min

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Variceal Ligation
Description: EVL will be done every 3 weeks till eradication

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Variceal Ligation
Description: EVL will be done every 3 weeks till eradication
Study: NCT04076761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/Tipiracil
Description: FTD/TPI is an orally administered combination of a thymidine-based nucleic acid analogue, trifluridine, and a thymidine phosphorylase inhibitor, tipiracil hydrochloride. Trifluridine is the active cytotoxic component of FTD/TPI; its triphosphate form is incorporated into DNA, with such incorporation appearing to result in its anti- tumor effects. Tipiracil hydrochloride is a potent inhibitor of thymidine phosphorylase and, when combined with trifluridine to form FTD/TPI, prevents the rapid degradation of the trifluridine, allowing for the maintenance of adequate plasma levels of the active drug.
Study: NCT00917410

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS support
Description: The intervention consisted of sequences of SMS messages sent to the intervention group, each containing 2 or 3 monitoring questions and one reminder to take the preventive medication. The SMS sequence was as follows.~1. Remember to take your preventive asthma medication (sent at 8.00 am).~2. Were you awakened during the night due to your asthma? Answer YES or NO.~3. How many times have you taken your asthma attack medication during the last 24 hours? Answer a number.~4. What was your peak flow this morning? Answer a number (optional, depending on the participant's use of a spirometer prior to the study).
Study: NCT03572634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-0903
Description: Monotherapy: PHASE 1: TP-0903 will be a 25 mg flat dose. The study drug will be administered orally once daily for 28 days (each cycle is 28 days; no drug-free period).~Patients may continue to receive TP-0903 in 28-day cycles at the same dose given during Cycle 1 until they experience unacceptable toxicity or unequivocal disease progression. No intrapatient escalation of the TP-0903 dose is permitted.~PHASE 2: The starting dose of TP-0903 will be the RP2D determined during Phase 1. TP 0903 will be administered orally at a fixed dose once daily for 28 days (each cycle is 28 days; no drug-free period) with repeated cycles permitted until a patient experiences unacceptable toxicity or unequivocal disease progression.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TP-0903 and ibrutinib combination therapy
Description: Combination therapy: PHASE 1: TP-0903 and ibrutinib combination therapy: The starting dose of TP-0903 will be a 20 mg flat dose. TP-0903 will be administered orally once daily for 28 days (each cycle is 28 days; no drug-free period). Patients will also receive ibrutinib at the same dose that they were receiving immediately prior to study enrollment.~Patients should continue with the combination of ibrutinib and TP-0903 for at least 3 months after study start.~PHASE 2: The starting dose of TP-0903 will be the RP2D determined during Phase 1. Patients will also receive ibrutinib at the same dose that they were receiving immediately prior to study enrollment. Both TP 0903 and ibrutinib will be administered orally at fixed doses once daily for 28 days (each cycle is 28 days; no drug-free period).
Study: NCT02100553

Intervention type: DRUG
Group type: OTHER
Intervention: CE/BZA
Description: CE 0.45mg/BZA 20mg tablets, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Itraconazole
Description: Two 100 mg capsules, once daily for 7 days

Intervention type: DRUG
Group type: OTHER
Intervention: CE/BZA
Description: CE 0.45mg/BZA 20mg tablets, single dose on Day 5

Intervention type: DRUG
Group type: OTHER
Intervention: CE/BZA
Description: CE 0.45mg/BZA 20mg tablets, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Itraconazole
Description: Two 100 mg capsules, once daily for 7 days

Intervention type: DRUG
Group type: OTHER
Intervention: CE/BZA
Description: CE 0.45mg/BZA 20mg tablets, single dose on Day 5
Study: NCT02396862

Intervention type: DRUG
Intervention: Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)
Description: Recombinant and Human Factor VIII / Used on demand or prophylaxis of bleeds
Study: NCT02525224

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Nutritional Supplement
Description: 2 Hard-shell liquid capsules taken twice daily with breakfast and dinner.
Study: NCT01312155

Intervention type: OTHER
Intervention: Intubation
Description: Intubation, endotracheal
Study: NCT03348683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: After induction is started with Foley or misoprostol placement, 30 minutes will pass before administration of the one-time study medication, IV Propanolol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After induction is started with Foley or misoprostol placement, 30 minutes will pass before administration of IV Saline
Study: NCT03633214

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online training module
Description: Responses of GPs in the intervention group will then be compared before and immediately after the online training video and also 3-months later; as well as to the control group.
Study: NCT01147939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacytarabine
Description: Elacytarabine 2000 mg/m2/d administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator's Choice
Description: E.g. cytarabine single agent/combinations, hypomethylating agents, best supportive care (BSC)
Study: NCT01975116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azurin-derived cell-penetrating peptide p28
Description: Given IV
Study: NCT03737032

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Theta Burst Stimulation
Description: Theta Burst Stimulation, a form of Transcranial Magnetic Stimulation, will be applied to the dorsomedial prefrontal cortex. will include 600 pulses delivered in brief bursts of three pulses with a frequency of 50 Hz, at an intensity of 110% of resting motor threshold, and administered every 200 ms (5 Hz). Bursts will be delivered during 2 second periods (10 bursts/period) interleaved with 8-second stimulation-free intervals, for a total duration of 190 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Theta Burst Stimulation
Description: Theta Burst Stimulation, a form of Transcranial Magnetic Stimulation, will be applied to the dorsomedial prefrontal cortex. will include 600 pulses delivered in brief bursts of three pulses with a frequency of 50 Hz, at an intensity of 110% of resting motor threshold, and administered every 200 ms (5 Hz). Bursts will be delivered during 2 second periods (10 bursts/period) interleaved with 8-second stimulation-free intervals, for a total duration of 190 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Theta Burst Stimulation
Description: Theta Burst Stimulation, a form of Transcranial Magnetic Stimulation, will be applied to the dorsomedial prefrontal cortex. will include 600 pulses delivered in brief bursts of three pulses with a frequency of 50 Hz, at an intensity of 110% of resting motor threshold, and administered every 200 ms (5 Hz). Bursts will be delivered during 2 second periods (10 bursts/period) interleaved with 8-second stimulation-free intervals, for a total duration of 190 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Theta Burst Stimulation
Description: Theta Burst Stimulation, a form of Transcranial Magnetic Stimulation, will be applied to the dorsomedial prefrontal cortex. will include 600 pulses delivered in brief bursts of three pulses with a frequency of 50 Hz, at an intensity of 110% of resting motor threshold, and administered every 200 ms (5 Hz). Bursts will be delivered during 2 second periods (10 bursts/period) interleaved with 8-second stimulation-free intervals, for a total duration of 190 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Theta Burst Stimulation
Description: Theta Burst Stimulation, a form of Transcranial Magnetic Stimulation, will be applied to the dorsomedial prefrontal cortex. will include 600 pulses delivered in brief bursts of three pulses with a frequency of 50 Hz, at an intensity of 110% of resting motor threshold, and administered every 200 ms (5 Hz). Bursts will be delivered during 2 second periods (10 bursts/period) interleaved with 8-second stimulation-free intervals, for a total duration of 190 seconds.
Study: NCT02155803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTHAR Gel (adrenocorticotropic hormone)
Description: ACTHAR GEL (adrenocorticotropic hormone) 80 units subcutaneously twice weekly for 12 weeks
Study: NCT00598130

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fleece
Description: Fibrin Patch

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fleece
Description: Fibrin Patch
Study: NCT04086940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol
Description: preventive

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol
Description: preventive
Study: NCT02124850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motolimod
Study: NCT03682809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systane Complete
Description: Systane Complete is an artificial tear indicated for patients who have evaporative, aqueous deficient, or mixed dry eye.
Study: NCT03066973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BREATHING EXERCISE
Description: The intervention group was instructed on breathing exercise according to the established trial protocol.
Study: NCT04515862

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding education
Description: The importance of breastfeeding Benefits of breastfeeding for mother and baby Structure of the breast and milk production Breastfeeding techniques and positions Breastfeeding problems and breast care
Study: NCT02361580

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diary
Description: Subject keeps diary of recovery
Study: NCT00531180

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 4D CT scans
Description: Three 4D CT scans will be performed. After you are out of the CT scanner, ventilation images will be calculated from the 4D CT images and will be compared with the standard ventilation imaging method.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung Function Imaging
Description: Lung function imaging performed to provide information on how well the lungs work, how air moves into the lungs with breathing, and blood circulation into the lungs.
Study: NCT06270745

Intervention type: DRUG
Intervention: indocyanine green
Description: Whether to use ICG to assess anastomotic perfusion during digestive system surgery

Intervention type: DRUG
Intervention: indocyanine green
Description: Whether to use ICG to assess anastomotic perfusion during digestive system surgery
Study: NCT02124850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motolimod

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study: NCT04807426

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multi Sensory stimulation exercises
Description: Multi Sensory stimulation exercises:Identification tasks will be given to a blindfolded patient. Which includes recognizing shapes, sizes , textures ,Identifying heights , hardness , weight discrimination .Difficulty will be added by increasing the objects to be identified. Joint angle perception training will be started with one joint perception and will advance to multiple joints position perception. Task Oriented Exercises: Patient will perform upper limb functional activities such as Reaching for objects, putting up and down an object, hand to mouth activity, combing hair, folding piece of cloth grasp and release activity, opening a jar, putting beads in jar and writing letters or draw something will be done. Complexity is added by increasing speed of task performance. Conservative Management:Passive stretching exercises for paretic upper extremity muscles .Stretchings will be applied for 30 sec with 30 sec rest, 10 repetitions for1 set.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task Oriented Exercises
Description: Task Oriented Exercises: Patient will perform upper limb functional activities such as Reaching for objects, putting up and down an object, hand to mouth activity, combing hair, folding piece of cloth grasp and release activity, opening a jar, putting beads in jar and writing letters or draw something will be done. Complexity will be added by increasing speed of task performance.~Conservative Management:Passive stretching exercises for paretic upper extremity muscles . Stretchings will be applied for 30 sec with 30 sec rest, 10 repetitions for1 set.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task-oriented exercises and Multisensory stimulation Exercises
Description: Multi Sensory stimulation exercises:Identification tasks will be given to a blindfolded patient. Which includes recognizing shapes, sizes , textures ,Identifying heights , hardness , weight discrimination .Difficulty will be added by increasing the objects to be identified. Joint angle perception training will be started with one joint perception and will advance to multiple joints position perception. Task Oriented Exercises: Patient will perform upper limb functional activities such as Reaching for objects, putting up and down an object, hand to mouth activity, combing hair, folding piece of cloth grasp and release activity, opening a jar, putting beads in jar and writing letters or draw something will be done. Complexity will be added by increasing speed of task performance.~Conservative Management:Passive stretching exercises for paretic upper extremity muscles . Stretchings will be applied for 30 sec with 30 sec rest, 10 repetitions for1 set.
Study: NCT04155450

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extension Biased External Limb Loading Exercises
Description: Begin in the quadruped position and progress the intensity by~1. Flexing one upper extremity~2. Extending one lower extremity with a leg slide~3. Extending one lower extremity by lifting it off the mat~4. Flexing one upper extremity while extending contralateral lower extremity and then alternate to opposite extremities.~   Progress to prone position:~5. Extending one lower extremity~6. Extending both lower extremity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: McKenzie Extension Exercise Protocol
Description: Static:~1. Lying Prone~2. Lying prone in extension~3. Sustained extension~4. Posture correction~   Dynamic:~5. Extension in lying~6. Extension in lying with clinician overpressure~7. Extension mobilization~8. Extension in standing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: McKenzie Extension Exercise Protocol
Description: Static:~1. Lying Prone~2. Lying prone in extension~3. Sustained extension~4. Posture correction~   Dynamic:~5. Extension in lying~6. Extension in lying with clinician overpressure~7. Extension mobilization~8. Extension in standing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moist Heat
Description: Moist Heating for 10 minutes at lumbar spine in prone position using moist heat packs, heated via hydro-collator.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moist Heat
Description: Moist Heating for 10 minutes at lumbar spine in prone position using moist heat packs, heated via hydro-collator.
Study: NCT04955093

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Technology to provide Heart Rate Variability Biofeedback
Study: NCT04242654

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Handheld fetal doppler ultrasound
Description: Handheld fetal doppler ultrasound will be used to assess heart rate in high-risk neonates.
Study: NCT01694394

Intervention type: DEVICE
Intervention: Implantable Cardiac Monitor (Confirm ICM model 2102)
Description: Patients who meet the study criteria will be implanted with a St. Jude Medical Confirm Implantable Cardiac Monitor (Confirm ICM) model 2102 or other St. Jude Medical ICM with the same capabilities.